

Attorney Docket No. IVD 994 US PCT

Reply under 37 C.F.R. 1.116  
Expedited Procedure  
Technology Center 1600**Claim Amendments:**

Claim 1. (Currently amended): A solid pharmaceutical composition in tablet form for oral administration comprising a benzofuran derivative with antiarrhythmic activity, or a pharmaceutically acceptable salt thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant selected from poloxamers, optionally in combination with one or more pharmaceutical excipients, said nonionic hydrophilic surfactant being present in a proportion of from 5% to 15% ~~1% to 50%~~ by weight of the active principle in base form.

Claim 2. (Previously presented): A pharmaceutical composition according to Claim 4, wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 3. (Previously presented): A pharmaceutical composition according to Claim 4, wherein the benzofuran derivative is amiodarone hydrochloride.

Claim 4. (Previously presented): A pharmaceutical composition according to Claim 14 wherein the pharmaceutically acceptable salt is the hydrochloride.

Claim 5. (Canceled)

Claim 6. (Currently amended): A pharmaceutical composition according to Claim 1 ~~Claim 5~~ wherein the nonionic hydrophilic surfactant is selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, ~~polyserbate 20, polyserbate 40, polyserbate 60, polyserbate 80 and the products Cremophor® RH 40 and Solutol® HS 15.~~

Claim 7. (Previously presented): A pharmaceutical composition according to Claim 15 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Attorney Docket No. IVD 994 US PC1

Reply under 37 C.F.R. 1.116  
Expedited Procedure  
Technology Center 1600

Claims 8-10 (Canceled)

Claim 11. (Previously presented): A pharmaceutical composition according to Claim 6 containing from 50 to 500 mg of active principle.

Claim 12. (Currently amended): A pharmaceutical composition according to Claim 11, ~~in tablet or gelatin capsule form,~~ containing from 200 to 400 mg of active principle.

Claim 13. (Currently amended): A pharmaceutical composition according to Claim 12, ~~in tablet or gelatin capsule form,~~ containing from 200 to 400 mg of active principle, calculated in base form, and 10% by weight of nonionic hydrophilic surfactant relative to the active principle in base form.

Claim 14. (Previously presented): A pharmaceutical composition according to Claim 1 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 15. (Previously presented): A pharmaceutical composition according to Claim 6 wherein the benzofuran derivative is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 16. (Previously presented): A pharmaceutical composition according to Claim 7 wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 17. (Canceled):

Attorney Docket No. 1VD 994 US PCT

Reply under 37 C.F.R. 1.116  
Expedited Procedure  
Technology Center 1600

Claim 18. (Currently amended): A pharmaceutical composition according to Claim 6 ~~Claim 17~~ wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claim 19. (Previously presented): A pharmaceutical composition according to Claim 18 wherein the benzofuran derivative is dronedarone hydrochloride.

Claim 20. (Previously presented): A pharmaceutical composition according to Claim 13 wherein the active principle is selected from the group consisting of amiodarone and dronedarone or a pharmaceutically acceptable salt thereof.

Claim 21. (Previously presented): A pharmaceutical composition according to claim 20 wherein the nonionic hydrophilic surfactant is poloxamer 407.

Claim 22. (Previously presented): A pharmaceutical composition according to claim 21 wherein the active principle is dronedarone hydrochloride.